Lotus Eye Hospital And Institute Share Price
Sector: Healthcare Facilities
74.39 +0.29 (0.39%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
73.00
Today’s High
75.54
52 Week Low
53.00
52 Week High
91.00
74.39 +0.90 (1.22%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
72.39
Today’s High
75.61
52 Week Low
52.35
52 Week High
90.98
Key Metrics
- Market Cap (In Cr) 154.7
- Beta 0.84
- Div. Yield (%) 0
- P/B 2.57
- TTM P/E 264.78
- Peg Ratio 12.72
- Sector P/E 22.82
- Open Price 74.65
- Prev Close 74.1
Lotus Eye Hospital And Institute Analysis
Price Analysis
-
1 Week-3.95%
-
3 Months23.62%
-
6 Month13.43%
-
YTD10.28%
-
1 Year20.57%
Risk Meter
- 49% Low risk
- 49% Moderate risk
- 49% Balanced Risk
- 49% High risk
- 49% Extreme risk
Lotus Eye Hospital And Institute News
Stocks to buy under ₹100: Sumeet Bagadia recommends 3 shares to buy on Monday
1 min read . 11 May 2025Stocks to buy under ₹100: Sumeet Bagadia recommends 3 shares to buy on Monday
1 min read . 04 May 2025Stocks to buy or sell under ₹100: Experts pick five intraday stocks for today
3 min read . 28 Apr 2025Stocks to buy under ₹100: Sumeet Bagadia recommends three shares to buy or sell
1 min read . 27 Apr 2025Lotus Eye Hospital And Institute Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 48.21
- Selling/ General/ Admin Expenses Total
- 18.75
- Depreciation/ Amortization
- 3.73
- Other Operating Expenses Total
- -0.44
- Total Operating Expense
- 44.97
- Operating Income
- 3.24
- Net Income Before Taxes
- 4.01
- Net Income
- 2.91
- Diluted Normalized EPS
- 1.4
- Period
- 2024
- Total Assets
- 66.63
- Total Liabilities
- 7.22
- Total Equity
- 59.41
- Tangible Book Valueper Share Common Eq
- 28.53
- Period
- 2024
- Cashfrom Operating Activities
- 5.68
- Cashfrom Investing Activities
- -4.63
- Cashfrom Financing Activities
- -3.4
- Net Changein Cash
- -2.35
- Period
- 2023
- Total Revenue
- 47.04
- Selling/ General/ Admin Expenses Total
- 8.88
- Depreciation/ Amortization
- 2.98
- Other Operating Expenses Total
- 8.59
- Total Operating Expense
- 42.44
- Operating Income
- 4.61
- Net Income Before Taxes
- 5.65
- Net Income
- 4.08
- Diluted Normalized EPS
- 1.96
- Period
- 2023
- Total Assets
- 63.19
- Total Liabilities
- 5.61
- Total Equity
- 57.58
- Tangible Book Valueper Share Common Eq
- 27.64
- Period
- 2023
- Cashfrom Operating Activities
- 4.39
- Cashfrom Investing Activities
- -2.19
- Cashfrom Financing Activities
- -1.71
- Net Changein Cash
- 0.49
- Period
- 2022
- Total Revenue
- 38.91
- Selling/ General/ Admin Expenses Total
- 7.31
- Depreciation/ Amortization
- 2.5
- Other Operating Expenses Total
- 7.47
- Total Operating Expense
- 35.55
- Operating Income
- 3.36
- Net Income Before Taxes
- 4.09
- Net Income
- 2.98
- Diluted Normalized EPS
- 1.44
- Period
- 2022
- Total Assets
- 61.6
- Total Liabilities
- 6.99
- Total Equity
- 54.61
- Tangible Book Valueper Share Common Eq
- 26.2
- Period
- 2022
- Cashfrom Operating Activities
- 4.39
- Cashfrom Investing Activities
- -3.92
- Cashfrom Financing Activities
- -1.58
- Net Changein Cash
- -1.1
- Period
- 2021
- Total Revenue
- 32.37
- Selling/ General/ Admin Expenses Total
- 6.97
- Depreciation/ Amortization
- 2.33
- Other Operating Expenses Total
- 6.64
- Total Operating Expense
- 31.14
- Operating Income
- 1.23
- Net Income Before Taxes
- 1.99
- Net Income
- 1.57
- Diluted Normalized EPS
- 0.72
- Period
- 2021
- Total Assets
- 59.23
- Total Liabilities
- 6.53
- Total Equity
- 52.7
- Tangible Book Valueper Share Common Eq
- 25.26
- Period
- 2021
- Cashfrom Operating Activities
- 2.74
- Cashfrom Investing Activities
- 0.49
- Cashfrom Financing Activities
- -0.33
- Net Changein Cash
- 2.9
- Period
- 2020
- Total Revenue
- 40.55
- Selling/ General/ Admin Expenses Total
- 8.94
- Depreciation/ Amortization
- 2.5
- Other Operating Expenses Total
- 9.36
- Total Operating Expense
- 39.23
- Operating Income
- 1.32
- Net Income Before Taxes
- 1.46
- Net Income
- 1.06
- Diluted Normalized EPS
- 0.76
- Period
- 2020
- Total Assets
- 58.44
- Total Liabilities
- 7.19
- Total Equity
- 51.26
- Tangible Book Valueper Share Common Eq
- 24.54
- Period
- 2020
- Cashfrom Operating Activities
- 4.81
- Cashfrom Investing Activities
- -0.53
- Cashfrom Financing Activities
- 0.13
- Net Changein Cash
- 4.42
- Period
- 2019
- Total Revenue
- 38.43
- Selling/ General/ Admin Expenses Total
- 9.38
- Depreciation/ Amortization
- 2.8
- Other Operating Expenses Total
- 8.25
- Total Operating Expense
- 38.41
- Operating Income
- 0.01
- Net Income Before Taxes
- 0.63
- Net Income
- 0.71
- Diluted Normalized EPS
- 0.42
- Period
- 2019
- Total Assets
- 56.52
- Total Liabilities
- 6.4
- Total Equity
- 50.12
- Tangible Book Valueper Share Common Eq
- 24
- Period
- 2019
- Cashfrom Operating Activities
- 4.2
- Cashfrom Investing Activities
- -4.01
- Cashfrom Financing Activities
- -1.41
- Net Changein Cash
- -1.22
- Period
- 2024-12-31
- Total Revenue
- 12.25
- Selling/ General/ Admin Expenses Total
- 2.96
- Depreciation/ Amortization
- 1.31
- Other Operating Expenses Total
- 2.33
- Total Operating Expense
- 12.76
- Operating Income
- -0.52
- Net Income Before Taxes
- -0.43
- Net Income
- -0.24
- Diluted Normalized EPS
- -0.11
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 12.91
- Selling/ General/ Admin Expenses Total
- 2.98
- Depreciation/ Amortization
- 1.23
- Other Operating Expenses Total
- 2.34
- Total Operating Expense
- 12.99
- Operating Income
- -0.08
- Net Income Before Taxes
- 0.11
- Net Income
- 0.1
- Diluted Normalized EPS
- 0.05
- Period
- 2024-09-30
- Total Assets
- 70.07
- Total Liabilities
- 9.97
- Total Equity
- 60.11
- Tangible Book Valueper Share Common Eq
- 28.87
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 3.16
- Cashfrom Investing Activities
- -3.62
- Cashfrom Financing Activities
- -0.61
- Net Changein Cash
- -1.08
- Period
- 2024-06-30
- Total Revenue
- 12.89
- Selling/ General/ Admin Expenses Total
- 2.81
- Depreciation/ Amortization
- 1.06
- Other Operating Expenses Total
- 2.32
- Total Operating Expense
- 12.28
- Operating Income
- 0.61
- Net Income Before Taxes
- 0.86
- Net Income
- 0.62
- Diluted Normalized EPS
- 0.3
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 10.88
- Selling/ General/ Admin Expenses Total
- 2.57
- Depreciation/ Amortization
- 1.12
- Other Operating Expenses Total
- 2.25
- Total Operating Expense
- 11.25
- Operating Income
- -0.36
- Net Income Before Taxes
- 0.01
- Net Income
- 0.02
- Diluted Normalized EPS
- 0.01
- Period
- 2024-03-31
- Total Assets
- 66.63
- Total Liabilities
- 7.22
- Total Equity
- 59.41
- Tangible Book Valueper Share Common Eq
- 28.53
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 5.68
- Cashfrom Investing Activities
- -4.63
- Cashfrom Financing Activities
- -3.4
- Net Changein Cash
- -2.35
- Period
- 2023-12-31
- Total Revenue
- 12.03
- Selling/ General/ Admin Expenses Total
- 2.53
- Depreciation/ Amortization
- 0.98
- Other Operating Expenses Total
- 2.23
- Total Operating Expense
- 11.43
- Operating Income
- 0.6
- Net Income Before Taxes
- 0.9
- Net Income
- 0.66
- Diluted Normalized EPS
- 0.32
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Lotus Eye Hospital And Institute Technical
Moving Average
SMA
- 5 Day75.24
- 10 Day74.87
- 20 Day74.33
- 50 Day67.61
- 100 Day66.95
- 300 Day69.74
Lotus Eye Hospital And Institute Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Forbes And Company
- 375.55
- -5.55
- -1.46
- 787.95
- 264.35
- 484.4
- Aashka Hospitals
- 96.9
- -0.1
- -0.1
- 126.55
- 65.26
- 226.75
- Lotus Eye Hospital And Institute
- 74.39
- 0.29
- 0.39
- 91
- 53
- 154.7
- Fortis Malar Hospitals
- 74.7
- 0.31
- 0.42
- 98.7
- 51.01
- 140
- Aspira Pathlab & Diagnostics
- 61.6
- 2.9
- 4.94
- 106.78
- 25
- 63.41
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Forbes And Company
- 17.12
- 2.29
- -36.13
- -7.89
- Aashka Hospitals
- 96.14
- 2.36
- 2.55
- 5.12
- Lotus Eye Hospital And Institute
- 52.62
- 2.58
- 4.65
- 6.09
- Fortis Malar Hospitals
- 18.31
- 1.28
- 1.1
- 1.17
- Aspira Pathlab & Diagnostics
- -
- 5.67
- -2.56
- -1.64
Lotus Eye Hospital And Institute Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 12-Feb-25
- Quarterly Results
- 12-Nov-24
- Quarterly Results
- 14-Aug-23
- Quarterly Results
- 24-May-23
- Audited Results & Dividend
- 13-Feb-23
- Quarterly Results
- 14-Nov-22
- Audited Results
- 09-Aug-22
- Quarterly Results
- 25-May-22
- Audited Results & Final Dividend
- 14-Feb-22
- Quarterly Results
- 13-Nov-21
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 13-Aug-24
- 27-May-24
- AGM
- 25-Sept-23
- 01-Sept-23
- AGM
- 21-Mar-23
- 16-Feb-23
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 25-May-23
- -
- 18-Sept-23
- 0.5
- 25-May-22
- 10-Sept-22
- 08-Sept-22
- 0.5
- 30-Jun-21
- -
- 08-Sept-21
- 0.5


